FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084447650> ?p ?o ?g. }

• W2084447650 endingPage "33" @default.
• W2084447650 startingPage "117" @default.
• W2084447650 abstract "It is well established that the use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) increase the vulnerability of the gastrointestinal (GI) mucosa for the development of peptic lesions and serious ulcer complications. In addition, selective and traditional NSAIDs have also been associated with increased frequency of cardiovascular toxicity, especially in susceptible patients. The objective of this communication is to provide an overview of the salient GI and cardiovascular (CV) toxicity for these drugs. Traditional NSAIDs inhibit the constitutional cyclooxygenase-1 (COX-1) enzyme responsible for eicosanoids biosynthesis not only in joints, a beneficial effect, but also in the stomach, a detrimental effect. Selective NSAIDs were specifically designed to preferentially inhibit the cyclooxygenase-2 (COX-2), an inducible enzyme mediating the production of inflammatory eicosanoids in the joints but sparing the endogenous protective eicosanoids in the stomach. Selective COX-2 inhibitors (COXIBs) have been shown to possess much improved GI tolerability and reduced GI related adverse events when compared with nonselective COX-1 inhibitors. An unexpected CV toxicity had emerged during the COXIBs post marketing outcome studies. Many subsequent studies were carried out to define the CV risks associated with COXIBs and NSAIDs. All COX inhibitors had shown this CV toxicity. In many clinical studies, rofecoxib use was associated with significantly more elevated CV risk when compared with celecoxib and non selective NSAIDs. The COX inhibitors associated CV toxicity has multiple manifestations, which include the induction of myocardial infarction (MI), edema, thrombosis, blood pressure destabilization and death. Patients at risk of CV disease or with a history of CV disease were the most significant determinants of CV events after receiving COX inhibitors. This CV toxicity not only led to the marketing withdrawal of rofecoxib and valdecoxib but also resulted in more restricted, but essentially identical, product labels in the United States for celecoxib and traditional NSAIDS. This CV toxicity is dose and treatment duration dependent and appears to be compound specific rather than COX specific. Additional comprehensive, long-term, prospective investigations comparing the CV and GI safety profile of marketed NSAIDs against each other and against selective inhibitors are needed to address the controversy of COX inhibitors." @default.
• W2084447650 created "2016-06-24" @default.
• W2084447650 creator A5024405378 @default.
• W2084447650 creator A5076695752 @default.
• W2084447650 date "2008-08-01" @default.
• W2084447650 modified "2023-09-25" @default.
• W2084447650 title "Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man." @default.
• W2084447650 cites W1576358752 @default.
• W2084447650 cites W174601305 @default.
• W2084447650 cites W1965992514 @default.
• W2084447650 cites W1972283919 @default.
• W2084447650 cites W1976110335 @default.
• W2084447650 cites W1976365391 @default.
• W2084447650 cites W1985210212 @default.
• W2084447650 cites W1989081972 @default.
• W2084447650 cites W1995355693 @default.
• W2084447650 cites W1995528018 @default.
• W2084447650 cites W2001162433 @default.
• W2084447650 cites W2001676690 @default.
• W2084447650 cites W2003614670 @default.
• W2084447650 cites W2010390914 @default.
• W2084447650 cites W2012920835 @default.
• W2084447650 cites W2018035901 @default.
• W2084447650 cites W2021041600 @default.
• W2084447650 cites W2027645788 @default.
• W2084447650 cites W2032997277 @default.
• W2084447650 cites W2037619899 @default.
• W2084447650 cites W2038410983 @default.
• W2084447650 cites W2038932922 @default.
• W2084447650 cites W2062335942 @default.
• W2084447650 cites W2063252400 @default.
• W2084447650 cites W2065689558 @default.
• W2084447650 cites W2067621583 @default.
• W2084447650 cites W2076700081 @default.
• W2084447650 cites W2080674779 @default.
• W2084447650 cites W2092193486 @default.
• W2084447650 cites W2097780727 @default.
• W2084447650 cites W2100631748 @default.
• W2084447650 cites W2110809844 @default.
• W2084447650 cites W2117935315 @default.
• W2084447650 cites W2132450168 @default.
• W2084447650 cites W2132552005 @default.
• W2084447650 cites W2134270369 @default.
• W2084447650 cites W2141792971 @default.
• W2084447650 cites W2145707658 @default.
• W2084447650 cites W2145816148 @default.
• W2084447650 cites W2148359829 @default.
• W2084447650 cites W2155820793 @default.
• W2084447650 cites W2163756514 @default.
• W2084447650 cites W2330496155 @default.
• W2084447650 cites W2467116370 @default.
• W2084447650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18812633" @default.
• W2084447650 hasPublicationYear "2008" @default.
• W2084447650 type Work @default.
• W2084447650 sameAs 2084447650 @default.
• W2084447650 citedByCount "28" @default.
• W2084447650 countsByYear W20844476502012 @default.
• W2084447650 countsByYear W20844476502013 @default.
• W2084447650 countsByYear W20844476502014 @default.
• W2084447650 countsByYear W20844476502015 @default.
• W2084447650 countsByYear W20844476502016 @default.
• W2084447650 countsByYear W20844476502017 @default.
• W2084447650 countsByYear W20844476502018 @default.
• W2084447650 countsByYear W20844476502019 @default.
• W2084447650 countsByYear W20844476502020 @default.
• W2084447650 countsByYear W20844476502022 @default.
• W2084447650 countsByYear W20844476502023 @default.
• W2084447650 crossrefType "journal-article" @default.
• W2084447650 hasAuthorship W2084447650A5024405378 @default.
• W2084447650 hasAuthorship W2084447650A5076695752 @default.
• W2084447650 hasConcept C126322002 @default.
• W2084447650 hasConcept C181199279 @default.
• W2084447650 hasConcept C185592680 @default.
• W2084447650 hasConcept C197934379 @default.
• W2084447650 hasConcept C2776467144 @default.
• W2084447650 hasConcept C2778375690 @default.
• W2084447650 hasConcept C2778582115 @default.
• W2084447650 hasConcept C2779689624 @default.
• W2084447650 hasConcept C2780886150 @default.
• W2084447650 hasConcept C29730261 @default.
• W2084447650 hasConcept C55493867 @default.
• W2084447650 hasConcept C71924100 @default.
• W2084447650 hasConcept C98274493 @default.
• W2084447650 hasConceptScore W2084447650C126322002 @default.
• W2084447650 hasConceptScore W2084447650C181199279 @default.
• W2084447650 hasConceptScore W2084447650C185592680 @default.
• W2084447650 hasConceptScore W2084447650C197934379 @default.
• W2084447650 hasConceptScore W2084447650C2776467144 @default.
• W2084447650 hasConceptScore W2084447650C2778375690 @default.
• W2084447650 hasConceptScore W2084447650C2778582115 @default.
• W2084447650 hasConceptScore W2084447650C2779689624 @default.
• W2084447650 hasConceptScore W2084447650C2780886150 @default.
• W2084447650 hasConceptScore W2084447650C29730261 @default.
• W2084447650 hasConceptScore W2084447650C55493867 @default.
• W2084447650 hasConceptScore W2084447650C71924100 @default.
• W2084447650 hasConceptScore W2084447650C98274493 @default.
• W2084447650 hasLocation W20844476501 @default.
• W2084447650 hasOpenAccess W2084447650 @default.

• next